X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DR. DATSONS LABS - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DR. DATSONS LABS AUROBINDO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 14.0 -10.9 - View Chart
P/BV x 3.6 0.2 2,207.6% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
DR. DATSONS LABS
Mar-14
AUROBINDO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs895126 712.6%   
Low Rs62231 2,012.9%   
Sales per share (Unadj.) Rs254.6133.0 191.4%  
Earnings per share (Unadj.) Rs39.30.2 25,906.8%  
Cash flow per share (Unadj.) Rs46.66.6 704.9%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.0128.8 124.2%  
Shares outstanding (eoy) m585.8831.66 1,850.5%   
Bonus/Rights/Conversions ESOPFCCB-  
Price / Sales ratio x3.00.6 506.4%   
Avg P/E ratio x19.3516.1 3.7%  
P/CF ratio (eoy) x16.311.8 137.5%  
Price / Book Value ratio x4.70.6 780.4%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,3902,477 17,937.8%   
No. of employees `00014.0NA-   
Total wages/salary Rs m17,67856 31,567.1%   
Avg. sales/employee Rs Th10,667.8NM-  
Avg. wages/employee Rs Th1,264.3NM-  
Avg. net profit/employee Rs Th1,645.8NM-  
INCOME DATA
Net Sales Rs m149,1574,211 3,542.5%  
Other income Rs m1,15979 1,472.6%   
Total revenues Rs m150,3164,289 3,504.5%   
Gross profit Rs m34,343569 6,039.9%  
Depreciation Rs m4,276204 2,092.1%   
Interest Rs m667430 155.1%   
Profit before tax Rs m30,55813 240,615.7%   
Minority Interest Rs m500-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5976 124,532.8%   
Profit after tax Rs m23,0125 479,414.6%  
Gross profit margin %23.013.5 170.5%  
Effective tax rate %24.948.0 51.8%   
Net profit margin %15.40.1 13,533.2%  
BALANCE SHEET DATA
Current assets Rs m92,0626,852 1,343.7%   
Current liabilities Rs m66,2236,711 986.8%   
Net working cap to sales %17.33.3 517.3%  
Current ratio x1.41.0 136.2%  
Inventory Days Days106161 65.9%  
Debtors Days Days68318 21.2%  
Net fixed assets Rs m62,9193,673 1,713.0%   
Share capital Rs m586317 185.1%   
"Free" reserves Rs m93,1333,761 2,476.3%   
Net worth Rs m93,7194,078 2,298.4%   
Long term debt Rs m1,8141,671 108.6%   
Total assets Rs m162,49412,633 1,286.3%  
Interest coverage x46.81.0 4,545.9%   
Debt to equity ratio x00.4 4.7%  
Sales to assets ratio x0.90.3 275.4%   
Return on assets %14.63.4 423.2%  
Return on equity %24.60.1 20,858.2%  
Return on capital %32.77.7 426.6%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m75,838964 7,867.0%   
Fx outflow Rs m30,224607 4,978.5%   
Net fx Rs m45,613357 12,780.4%   
CASH FLOW
From Operations Rs m32,7861,345 2,438.0%  
From Investments Rs m-17,870-2,256 792.3%  
From Financial Activity Rs m-19,153-1,200 1,596.3%  
Net Cashflow Rs m-4,239-2,111 200.8%  

Share Holding

Indian Promoters % 54.1 4.5 1,194.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.0 -  
FIIs % 27.7 1.4 2,051.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 94.1 10.8%  
Shareholders   69,601 20,807 334.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  MERCK LTD  BIOCON LTD  J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS